AU2011347243A1 - Pharmaceutical compositions of pyridinium and quinolinium derivatives - Google Patents
Pharmaceutical compositions of pyridinium and quinolinium derivatives Download PDFInfo
- Publication number
- AU2011347243A1 AU2011347243A1 AU2011347243A AU2011347243A AU2011347243A1 AU 2011347243 A1 AU2011347243 A1 AU 2011347243A1 AU 2011347243 A AU2011347243 A AU 2011347243A AU 2011347243 A AU2011347243 A AU 2011347243A AU 2011347243 A1 AU2011347243 A1 AU 2011347243A1
- Authority
- AU
- Australia
- Prior art keywords
- cyclodextrin
- composition according
- substituted
- alkyl
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Nanotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Crystallography & Structural Chemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10382348.0 | 2010-12-23 | ||
EP10382348A EP2468259A1 (fr) | 2010-12-23 | 2010-12-23 | Compositions pharmaceutiques de dérivés de pyridinium et de quinolinium |
US201161492621P | 2011-06-02 | 2011-06-02 | |
US61/492,621 | 2011-06-02 | ||
PCT/EP2011/073722 WO2012085171A2 (fr) | 2010-12-23 | 2011-12-22 | Compositions pharmaceutiques de dérivés de pyridinium et de quinolinium |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2011347243A1 true AU2011347243A1 (en) | 2013-07-04 |
Family
ID=43858363
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2011347243A Abandoned AU2011347243A1 (en) | 2010-12-23 | 2011-12-22 | Pharmaceutical compositions of pyridinium and quinolinium derivatives |
Country Status (15)
Country | Link |
---|---|
US (1) | US20150037397A1 (fr) |
EP (2) | EP2468259A1 (fr) |
JP (1) | JP2014500297A (fr) |
KR (1) | KR20140017516A (fr) |
CN (1) | CN103313701A (fr) |
AU (1) | AU2011347243A1 (fr) |
BR (1) | BR112013015813A2 (fr) |
CA (1) | CA2821230A1 (fr) |
DK (1) | DK2654721T3 (fr) |
ES (1) | ES2529673T3 (fr) |
MX (1) | MX2013006851A (fr) |
PL (1) | PL2654721T3 (fr) |
PT (1) | PT2654721E (fr) |
RU (1) | RU2013134249A (fr) |
WO (1) | WO2012085171A2 (fr) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
CN1232539C (zh) * | 2002-05-10 | 2005-12-21 | 刘云清 | 有机药物与倍他环糊精衍生物的配合物及其制备方法 |
ES2237332B1 (es) * | 2004-01-14 | 2006-11-01 | Consejo Sup. Investig. Cientificas | Derivados de piridinio y quinolinio. |
CN1593387A (zh) * | 2004-06-21 | 2005-03-16 | 沈阳药科大学 | 包封两亲性药物的脂质体的制备方法及其制剂 |
TW200726485A (en) * | 2005-07-01 | 2007-07-16 | Alza Corp | Liposomal delivery vehicle for hydrophobic drugs |
US20100068302A1 (en) * | 2008-09-17 | 2010-03-18 | Traslational Cancer Drugs Pharma, S.L. | Methods and compositions for the treatment of cancer |
AU2010312078B2 (en) * | 2009-10-26 | 2015-10-08 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Liposome having inner water phase containing sulfobutyl ether cyclodextrin salt |
-
2010
- 2010-12-23 EP EP10382348A patent/EP2468259A1/fr not_active Withdrawn
-
2011
- 2011-12-22 PL PL11805029T patent/PL2654721T3/pl unknown
- 2011-12-22 CN CN201180062062XA patent/CN103313701A/zh active Pending
- 2011-12-22 JP JP2013545393A patent/JP2014500297A/ja active Pending
- 2011-12-22 WO PCT/EP2011/073722 patent/WO2012085171A2/fr active Application Filing
- 2011-12-22 KR KR1020137017080A patent/KR20140017516A/ko not_active Application Discontinuation
- 2011-12-22 CA CA2821230A patent/CA2821230A1/fr not_active Abandoned
- 2011-12-22 ES ES11805029.3T patent/ES2529673T3/es active Active
- 2011-12-22 BR BR112013015813A patent/BR112013015813A2/pt not_active IP Right Cessation
- 2011-12-22 MX MX2013006851A patent/MX2013006851A/es active IP Right Grant
- 2011-12-22 DK DK11805029.3T patent/DK2654721T3/en active
- 2011-12-22 AU AU2011347243A patent/AU2011347243A1/en not_active Abandoned
- 2011-12-22 PT PT118050293T patent/PT2654721E/pt unknown
- 2011-12-22 US US13/996,887 patent/US20150037397A1/en not_active Abandoned
- 2011-12-22 EP EP11805029.3A patent/EP2654721B1/fr active Active
- 2011-12-22 RU RU2013134249/15A patent/RU2013134249A/ru not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP2468259A1 (fr) | 2012-06-27 |
PT2654721E (pt) | 2015-02-10 |
EP2654721A2 (fr) | 2013-10-30 |
US20150037397A1 (en) | 2015-02-05 |
CN103313701A (zh) | 2013-09-18 |
EP2654721B1 (fr) | 2014-11-19 |
MX2013006851A (es) | 2013-07-29 |
PL2654721T3 (pl) | 2015-04-30 |
DK2654721T3 (en) | 2015-02-23 |
BR112013015813A2 (pt) | 2018-05-29 |
WO2012085171A2 (fr) | 2012-06-28 |
RU2013134249A (ru) | 2015-01-27 |
WO2012085171A3 (fr) | 2012-10-11 |
JP2014500297A (ja) | 2014-01-09 |
KR20140017516A (ko) | 2014-02-11 |
CA2821230A1 (fr) | 2012-06-28 |
ES2529673T3 (es) | 2015-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0616529B1 (fr) | Compositions de medicaments pour usage parenteral | |
KR102310786B1 (ko) | 리포좀 내로 난수용성 약물의 원격 부하 | |
US6653319B1 (en) | Pharmaceutical formulation for poorly water soluble camptothecin analogues | |
EP2086513B1 (fr) | Nanoparticule submicronique de dérivés de camptothécine faiblement solubles dans l'eau et son procédé de préparation | |
US20140220112A1 (en) | Transformation of drug cyclodextrin complex compositions into compositions of mixtures of lipid vesicle encapsulated drug and cyclodextrin drug complexes | |
JPH11506463A (ja) | 親脂性に富んだカンプトテシン誘導体治療薬 | |
KR100711315B1 (ko) | 리포좀 캄프토테신 제제 | |
Tang et al. | A simple and improved active loading method to efficiently encapsulate staurosporine into lipid-based nanoparticles for enhanced therapy of multidrug resistant cancer | |
JP6230538B2 (ja) | 安定なオキサリプラチン封入リポソーム水分散液及びその安定化方法 | |
EP1396266A1 (fr) | Preparation de cilostazol aqueuse pour injections | |
KR101874764B1 (ko) | 음이온-양이온성 환형다당류 조성물인 벤다무스틴 | |
AU767474B2 (en) | Liposome compositions for improved drug retention | |
DK2654721T3 (en) | Pharmaceutical preparations of pyridinium and quinolinium derivatives | |
JP2023551145A (ja) | 医薬化合物の錯化剤塩製剤 | |
JPWO2005077370A1 (ja) | カンプトテシン類含有水溶液製剤 | |
JP2001527037A (ja) | Z−4−ヒドロキシタモキシフェン及びシクロデキストリンを含む混合物及び薬剤学的組成 | |
CZ2006403A3 (cs) | Farmaceutická kompozice pro injekcní podání | |
US20150057305A1 (en) | Pharmaceutical composition | |
JP2005521712A (ja) | 弱塩基の可溶化 | |
US20070148221A1 (en) | Method of producing lipid complexed camptothecin-carboxylate | |
WO2023225113A1 (fr) | Formulations de sel d'agent complexant de composés pharmaceutiques à de faibles rapports stœchiométriques | |
CA2456970C (fr) | Formulation de medicaments pour administration parenterale |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |